$VTVT
vTv Therapeutics Inc. Stock $vtvt

$vtvt Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000119312515376707 Filed on November 13, 2015

Income Statement

Concept	2015 Q3	2014 Q4	2014 Q3
Revenue	$133.0K	$934.0K	$400.0K
YoY Change	-66.75%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.420M	$2.140M	$1.590M
YoY Change	52.2%
% of Gross Profit
Research & Development	$6.574M	$5.460M	$4.037M
YoY Change	62.84%
% of Gross Profit
Depreciation & Amortization	$110.0K	$180.0K	$230.0K
YoY Change	-52.17%
% of Gross Profit
Operating Expenses	$9.574M	$7.600M	$5.920M
YoY Change	61.72%
Operating Profit	-$9.441M	-$6.668M	-$5.520M
YoY Change	71.03%
Interest Expense	$4.000K	-$400.0K	-$33.00K
YoY Change	-112.12%
% of Operating Profit
Other Income/Expense, Net	-$1.000K	-$650.0K	-$25.00K
YoY Change	-96.0%
Pretax Income	-$9.822M	-$7.720M	-$5.870M
YoY Change	67.33%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.103M	-$7.715M	-$5.870M
YoY Change	-30.1%
Net Earnings / Revenue	-3084.96%	-826.02%	-1467.5%
Basic Earnings Per Share
Diluted Earnings Per Share	-$493.4K	-$235.3K	-$178.9K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$97.00M	$1.400M
YoY Change
Cash & Equivalents	$97.01M	$1.384M	$1.045M
Short-Term Investments
Other Short-Term Assets	$800.0K	$200.0K
YoY Change
Inventory
Prepaid Expenses
Receivables	$0.00	$0.00
Other Receivables		$0.00
Total Short-Term Assets	$97.81M	$1.611M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$669.0K	$3.778M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.669M	$110.0K
YoY Change
Total Long-Term Assets	$2.386M	$11.34M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$97.81M	$1.611M
Total Long-Term Assets	$2.386M	$11.34M
Total Assets	$100.2M	$12.95M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.800M	$2.042M
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$155.0K
YoY Change
Long-Term Debt Due	$0.00	$200.0K
YoY Change
Total Short-Term Liabilities	$6.076M	$6.864M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$2.110M
YoY Change
Other Long-Term Liabilities	$53.00K	$4.434M
YoY Change
Total Long-Term Liabilities	$53.00K	$6.544M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.076M	$6.864M
Total Long-Term Liabilities	$53.00K	$6.544M
Total Liabilities	$6.129M	$73.67M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$211.6M
YoY Change
Common Stock	$117.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$94.19M	-$498.8M
YoY Change
Total Liabilities & Shareholders Equity	$100.2M	$12.95M
YoY Change

Cashflow Statement

Concept	2015 Q3	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$4.103M	-$7.715M	-$5.870M
YoY Change	-30.1%
Depreciation, Depletion And Amortization	$110.0K	$180.0K	$230.0K
YoY Change	-52.17%
Cash From Operating Activities	-$9.830M	-$6.980M	-$5.560M
YoY Change	76.8%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$10.00K	-$10.00K
YoY Change	0.0%
Acquisitions
YoY Change
Other Investing Activities		$190.0K
YoY Change
Cash From Investing Activities	-$10.00K	$200.0K	-$10.00K
YoY Change	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	104.4M	7.120M	4.960M
YoY Change	2005.65%
NET CHANGE
Cash From Operating Activities	-9.830M	-6.980M	-5.560M
Cash From Investing Activities	-10.00K	200.0K	-10.00K
Cash From Financing Activities	104.4M	7.120M	4.960M
Net Change In Cash	94.60M	340.0K	-610.0K
YoY Change	-15608.2%
FREE CASH FLOW
Cash From Operating Activities	-$9.830M	-$6.980M	-$5.560M
Capital Expenditures	-$10.00K	$10.00K	-$10.00K
Free Cash Flow	-$9.820M	-$6.990M	-$5.550M
YoY Change	76.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1045000
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	0	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	831934	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	8.73
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	0	shares
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	117131000
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	-94185000
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	53000
CY2015Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5240000
CY2015Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	188251000
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	320000
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211645000
CY2015Q3	us-gaap	Liabilities Liabilities	6129000
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100195000
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6076000
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6900000
CY2015Q3	us-gaap	Due From Employees Noncurrent DueFromEmployeesNoncurrent	48000
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1669000
CY2015Q3	us-gaap	Assets Assets	100195000
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	669000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0
CY2015Q3	us-gaap	Assets Current AssetsCurrent	97809000
CY2015Q3	us-gaap	Fair Value Equity Level1 To Level2 Transfers Amount FairValueEquityLevel1ToLevel2TransfersAmount	0
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	799000
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97010000
CY2015Q3	vtvt	Accounts Payable And Accrued Expenses Related Party AccountsPayableAndAccruedExpensesRelatedParty	516000
CY2015Q3	vtvt	Redeemable Noncontrolling Interest Temporary Equity Redemption Value RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue	188200000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1089000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	0	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	6594000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-498806000
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2110000
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4434000
CY2014Q4	us-gaap	Members Equity MembersEquity	-498806000
CY2014Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	155000
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3079000
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1878000
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	438086000
CY2014Q4	us-gaap	Liabilities Liabilities	73671000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12951000
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6864000
CY2014Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	2800000
CY2014Q4	us-gaap	Due From Employees Noncurrent DueFromEmployeesNoncurrent	58000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	110000
CY2014Q4	us-gaap	Assets Assets	12951000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3778000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	1611000
CY2014Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	6594000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	130000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	97000
CY2014Q4	us-gaap	Accounts Receivable Related Parties Noncurrent AccountsReceivableRelatedPartiesNoncurrent	800000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1384000
CY2014Q4	vtvt	Accounts Payable And Accrued Expenses Related Party AccountsPayableAndAccruedExpensesRelatedParty	1752000
CY2014Q4	vtvt	Debt Due To Related Party DebtDueToRelatedParty	27310000
CY2014Q4	vtvt	Fair Value Of Contingent Distribution FairValueOfContingentDistribution	26359000
CY2015Q3	us-gaap	Key Provisions Of Operating Or Partnership Agreement Description KeyProvisionsOfOperatingOrPartnershipAgreementDescription	One managing member unit, which represents no economic interests and has 100% of the voting power of vTv LLC
CY2015Q3	vtvt	Percentage Of Amount Of Cash Savings PercentageOfAmountOfCashSavings	0.85	pure
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-23800000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000
	us-gaap	Net Income Loss NetIncomeLoss	-28386000
	us-gaap	Sales Revenue Net SalesRevenueNet	615000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-109000
	us-gaap	Profit Loss ProfitLoss	-28386000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	68000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22229000
	us-gaap	Increase Decrease In Due From Employee Current IncreaseDecreaseInDueFromEmployeeCurrent	32000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	144000
	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	173000
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	230000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28386000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	5562000
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-110000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-44000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	12000
	us-gaap	Operating Expenses OperatingExpenses	22844000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-35000
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	145000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	23791000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12209000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	76000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2183000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9577000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	23901000
	us-gaap	Depreciation Depreciation	681000
	vtvt	Number Of Customers NumberOfCustomers	2	Customer
	vtvt	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	1058000
	vtvt	Investment Income Loss Related Party InvestmentIncomeLossRelatedParty	-9000
	vtvt	Increase Decrease In Accounts Payable And Accrued Liabilities Related Parties IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties	1484000
	vtvt	Change In Fair Value Of Marketable Securities Related Party ChangeInFairValueOfMarketableSecuritiesRelatedParty	39000
	vtvt	Bad Debt Expense Related Party BadDebtExpenseRelatedParty	230000
	vtvt	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	4773000
	vtvt	Other Income Expenses Related Party OtherIncomeExpensesRelatedParty	-466000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-27976000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	833934	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001641489
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	2000	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentration of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 13%"> Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The accounts receivable balance at September 30, 2015 was $0.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 13%"> One customer represented 100% of the revenue earned during the three and nine months ended September 30, 2015. Two customers represented 100% of the revenue during the three and nine months ended September 30, 2014.</p> </div>
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of Class A Common Stock and Class B Common Stock will be entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval.
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	vTv Therapeutics Inc.
	us-gaap	Temporary Equity Issue Period Increase Or Decrease TemporaryEquityIssuePeriodIncreaseOrDecrease	-75077000
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	6.56
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.73
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 13%"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 13%"> On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of the Company’s membership units, the fair value of redeemable preferred units, the fair value of derivative liabilities, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</p> </div>
	us-gaap	Key Provisions Of Operating Or Partnership Agreement Description KeyProvisionsOfOperatingOrPartnershipAgreementDescription	Non-voting vTv Units, which represent economic interests
	dei	Trading Symbol TradingSymbol	VTVT
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	95626000
	us-gaap	Operating Expenses OperatingExpenses	27345000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-42000
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	48000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	123644000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19106000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1012000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1544000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	300000
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	Segment
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42000
	us-gaap	Net Income Loss NetIncomeLoss	-24329000
	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-209427000
	us-gaap	Sales Revenue Net SalesRevenueNet	293000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-86000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	304000
	us-gaap	Profit Loss ProfitLoss	-30048000
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	104445000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	705000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27052000
	us-gaap	Increase Decrease In Due From Employee Current IncreaseDecreaseInDueFromEmployeeCurrent	-12000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-851000
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	12461000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1594000
	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	20000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30048000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Share Based Compensation ShareBasedCompensation	304000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	320000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	27000
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	1667000
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	2746000
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-89000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6707000
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	12461000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	105773000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	19289000
	us-gaap	Depreciation Depreciation	361000
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5719000
	vtvt	Percentage Of Amount Of Cash Savings PercentageOfAmountOfCashSavings	0.85	pure
	vtvt	Number Of Customers NumberOfCustomers	1	Customer
	vtvt	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	1532000
	vtvt	Number Of Properties Sold NumberOfPropertiesSold	1	Property
	vtvt	Effect Of Reorganization Transactions In Value EffectOfReorganizationTransactionsInValue	596244000
	vtvt	Increase Decrease In Accounts Payable And Accrued Liabilities Related Parties IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties	2094000
	vtvt	Bad Debt Expense Related Party BadDebtExpenseRelatedParty	-2000
	vtvt	Change In Fair Value Of Contingent Distribution ChangeInFairValueOfContingentDistribution	695000
	vtvt	Other Income Expenses Related Party OtherIncomeExpensesRelatedParty	-392000
	vtvt	Cash Payments On Repurchase Of Units Number Of Installments CashPaymentsOnRepurchaseOfUnitsNumberOfInstallments	8	Installments
	vtvt	Distribution Made To Limited Liability Company Llc Member Distributions Payments Description DistributionMadeToLimitedLiabilityCompanyLlcMemberDistributionsPaymentsDescription	This right was exercisable at the earlier to occur of (1) the maturity of the 2007 Note or (2) the date the Former Officer receives distribution payable payments under the Former Officer Agreement in excess of $30 million.
	vtvt	Net Income Loss Subsequent To Reorganization Transactions NetIncomeLossSubsequentToReorganizationTransactions	-2218000
	vtvt	Net Income Loss Prior To Reorganization Transactions NetIncomeLossPriorToReorganizationTransactions	-22111000
	vtvt	Payment Of Offering Cost Related Party PaymentOfOfferingCostRelatedParty	1329000
	vtvt	Tax Receivable Agreement Description TaxReceivableAgreementDescription	The Tax Receivable Agreement among the Company, vTv Therapeutics Holdings and M&F TTP Holdings LLC (“M&F”) provides for the payment by the Company to vTv Therapeutics Holdings (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
	vtvt	Increase Decrease In Redemption Value Of Noncontrolling Interest IncreaseDecreaseInRedemptionValueOfNoncontrollingInterest	209427000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-5870000
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	400000
CY2014Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-33000
CY2014Q3	us-gaap	Profit Loss ProfitLoss	-5870000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5520000
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5870000
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2014Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	170000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	5920000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4037000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1592000
CY2014Q3	vtvt	Number Of Customers NumberOfCustomers	2	Customer
CY2014Q3	vtvt	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	291000
CY2014Q3	vtvt	Other Income Expenses Related Party OtherIncomeExpensesRelatedParty	-122000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-4103000
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	133000
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	4000
CY2015Q3	us-gaap	Profit Loss ProfitLoss	-9822000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9441000
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9822000
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2015Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	328000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	9574000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6574000
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	300000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2415000
CY2015Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5719000
CY2015Q3	vtvt	Number Of Customers NumberOfCustomers	1	Customer
CY2015Q3	vtvt	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	585000
CY2015Q3	vtvt	Other Income Expenses Related Party OtherIncomeExpensesRelatedParty	-56000

Files In Submission

Name	View Source	Status
0001193125-15-376707-index-headers.html	Edgar Link	pending
0001193125-15-376707-index.html	Edgar Link	pending
0001193125-15-376707.txt	Edgar Link	pending
0001193125-15-376707-xbrl.zip	Edgar Link	pending
d92891d10q.htm	Edgar Link	pending
d92891dex311.htm	Edgar Link	pending
d92891dex312.htm	Edgar Link	pending
d92891dex321.htm	Edgar Link	pending
d92891dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vtvt-20150930.xml	Edgar Link	completed
vtvt-20150930.xsd	Edgar Link	pending
vtvt-20150930_cal.xml	Edgar Link	unprocessable
vtvt-20150930_def.xml	Edgar Link	unprocessable
vtvt-20150930_lab.xml	Edgar Link	unprocessable
vtvt-20150930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VTVT
vTv Therapeutics Inc. Stock $vtvt

2015 Q3 Form 10-Q Financial Statement

#000119312515376707 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VTVT vTv Therapeutics Inc. Stock $vtvt

2015 Q3 Form 10-Q Financial Statement

#000119312515376707 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VTVT
vTv Therapeutics Inc. Stock $vtvt